Camrelizumab Plus Nab-Paclitaxel and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer: a Randomized Phase III Trial
A Phase III, Open-Label, Multicenter, Randomized Clinical Trial of Neoadjuvant Camrelizumab Combined With Nab-Paclitaxel and Cisplatin in Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
This is a Phase III, randomized, open-label, multicenter clinical study for patients with locally advanced, resectable head and neck squamous cell carcinoma (HNSCC).
The current standard treatment for this disease includes surgery or radiation, but many patients still experience tumor recurrence or metastasis. This study aims to evaluate whether adding an immunotherapy drug (Camrelizumab) to standard chemotherapy (nab-paclitaxel and cisplatin) before surgery or radiation can improve patient outcomes.
Participants will be randomly assigned in a 1:1 ratio to one of two groups:
Experimental Group: Receives 3 cycles of Camrelizumab combined with nab-paclitaxel and cisplatin as neoadjuvant (pre-operative) therapy.
Control Group: Receives 3 cycles of nab-paclitaxel and cisplatin as neoadjuvant therapy.
After 3 cycles of treatment, doctors will evaluate the tumors. Depending on the tumor response, its location, and the patient's preference, participants will then receive either surgery (radical resection) or radiation therapy combined with cisplatin.
The main goal of this study is to compare the 2-year Event-Free Survival (EFS) between the two groups to see if the addition of Camrelizumab can prevent the disease from progressing or coming back. We will also monitor overall survival, organ preservation rates, and safety.
研究概览
详细说明
Background:
Head and neck squamous cell carcinoma (HNSCC) is a common malignancy worldwide. For locally advanced resectable HNSCC, the standard treatment paradigm often involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. However, the 5-year survival rate remains suboptimal, and the optimal neoadjuvant regimen is still debated. Immunotherapy, particularly PD-1 inhibitors, has shown promising efficacy in recurrent/metastatic HNSCC. Our previous Phase II trial demonstrated that neoadjuvant Camrelizumab combined with nab-paclitaxel and cisplatin was safe and highly effective (Objective Response Rate of 89.6%). This Phase III study is designed to further validate these findings.
Study Design:
This is a randomized, open-label, multicenter, Phase III clinical trial. A total of 212 eligible patients with clinical stage III-IV (T2N2-3M0, T3-4N0-3M0, AJCC 8th) resectable HNSCC will be enrolled and randomized 1:1 to the experimental or control group.
Interventions:
Experimental Arm: Neoadjuvant Camrelizumab (200 mg, IV, Day 1) + nab-paclitaxel (260 mg/m², IV, Day 1) + cisplatin (60 mg/m², IV, Day 1) for 3 cycles (21-day cycle).
Control Arm: Neoadjuvant nab-paclitaxel (260 mg/m², IV, Day 1) + cisplatin (60 mg/m², IV, Day 1) for 3 cycles.
After 3 cycles, tumor response will be evaluated per RECIST v1.1. Patients with oropharyngeal, laryngeal, or hypopharyngeal cancer who achieve CR/PR and wish to preserve organ function will receive radical radiotherapy plus cisplatin; those with residual disease will undergo salvage surgery. Other patients will undergo radical surgery with organ preservation. Adjuvant therapy will be administered based on NCCN/CSCO guidelines and multidisciplinary team discussion.
Outcomes:
The primary endpoint is 2-year Event-Free Survival (EFS). Secondary endpoints include 2-year Overall Survival (OS), 2-year Progression-Free Survival (PFS), organ preservation rate, Disease Control Rate (DCR), Objective Response Rate (ORR), safety, quality of life (EORTC QLQ-C30 and QLQ-H&N35), and exploratory biomarker analysis (PD-L1 CPS, TMB, etc.).
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Xuekui Liu, MD, PhD
- 电话号码:020-87343009
- 邮箱:liuxuek@sysucc.org.cn
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
1. Histologically and/or cytologically confirmed, previously untreated head and neck squamous cell carcinoma (diagnostic treatment excluded).
2. Clinical stage T2N2-3M0 or T3-4N0-3M0 (Stage III-IV, AJCC 8th edition). 3. Age between 18 and 70 years. 4. ECOG Performance Status (PS) of 0 or 1. 5. Assessed by a head and neck oncologist as resectable with no distant metastasis.
6. At least one evaluable lesion according to RECIST v1.1. 7. Adequate organ function to tolerate surgery:
-
Hematology: WBC ≥ 4000/μL, ANC ≥ 2.000/μL, Hemoglobin ≥ 9 g/dL, Platelets ≥ 100,000/μL.
-
Liver function: Bilirubin ≤ 1.5× ULN, AST/ALT ≤ 3× ULN, ALP ≤ 3× ULN, Albumin ≥ 3 g/dL.
-
Renal function: Serum creatinine ≤ 1.5× ULN or Cockcroft-Gault creatinine clearance ≥ 60 mL/min.
8. Signed informed consent and willingness to comply with study procedures.
Exclusion Criteria:
-
1. History of severe hypersensitivity to other monoclonal antibodies or any component of PD-1 monoclonal antibodies.
2. Known or suspected autoimmune diseases, including dementia and epilepsy. 3. Recurrent disease, distant metastasis, concurrent other malignancies, or assessed as unresectable.
4. Coagulation abnormalities (PT > 16s, APTT > 53s, TT > 21s, Fib < 1.5g/L), bleeding tendency, or receiving thrombolytic/anticoagulant therapy.
5. Severe heart or lung disease; cardiac or pulmonary function below grade 3 (including grade 3).
6. Laboratory test values within 7 days prior to enrollment not meeting the relevant standards.
7. Prior use of anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies (or any other antibody targeting T-cell co-stimulation or checkpoint pathways).
8. Comorbidities requiring long-term immunosuppressive therapy or systemic/local use of immunosuppressive doses of corticosteroids prior to enrollment.
9. HIV positive; HBsAg positive with detectable HBV DNA (≥ 1000 cps/ml); positive blood screening for chronic hepatitis C (HCV antibody positive).
10. Use of anti-tumor traditional Chinese herbal medicine within 4 weeks prior to randomization.
11. Pregnant or lactating women.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Camrelizumab plus Chemotherapy
Patients receive neoadjuvant Camrelizumab (200 mg, IV, Day 1) combined with nab-paclitaxel (260 mg/m², IV, Day 1) and cisplatin (60 mg/m², IV, Day 1) every 3 weeks for 3 cycles, followed by surgery or radiotherapy based on tumor response. |
Humanized anti-PD-1 monoclonal antibody administered intravenously at 200 mg on Day 1 of each 21-day cycle for 3 cycles.
其他名称:
Administered intravenously at 260 mg/m² on Day 1 of each 21-day cycle for 3 cycles.
其他名称:
Administered intravenously at 60 mg/m² on Day 1 of each 21-day cycle for 3 cycles.
其他名称:
|
|
有源比较器:Chemotherapy Alone
Patients receive neoadjuvant nab-paclitaxel (260 mg/m², IV, Day 1) and cisplatin (60 mg/m², IV, Day 1) every 3 weeks for 3 cycles, followed by surgery or radiotherapy based on tumor response. |
Administered intravenously at 260 mg/m² on Day 1 of each 21-day cycle for 3 cycles.
其他名称:
Administered intravenously at 60 mg/m² on Day 1 of each 21-day cycle for 3 cycles.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
2-year Event-Free Survival (EFS) Rate
大体时间:2 years from randomization
|
Event-Free Survival (EFS) is defined as the time from randomization to the first occurrence of any of the following events: disease progression that precludes surgery, local or distant recurrence, treatment termination due to toxicity or complications, or death from any cause. The rate at 2 years will be calculated. |
2 years from randomization
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
2-year Overall Survival (OS) Rate
大体时间:2 years from randomization
|
The percentage of patients alive at 2 years from randomization. If the patient died within 2 years, it will be censored at the last known alive date. |
2 years from randomization
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- B2024-782
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.